IGC AMEX
IGC Pharma, Inc.
1W: -2.7%
1M: -7.1%
3M: -2.2%
YTD: -5.5%
1Y: -33.2%
3Y: -23.1%
5Y: -82.0%
$0.27
+0.00 (+1.81%)
Weekly Expected Move ±5.9%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (26)
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%
IGC Pharma (NYSEAMERICAN:IGC) Shares Up 0.9% – Still a Buy?
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
IGC Pharma reports results
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Short Interest Up 15.9% in February
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
IGC Pharma (NYSEAMERICAN:IGC) Stock Price Down 1.2% – Time to Sell?
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
IGC Pharma Announces Equity Research Update by Alliance Global Partners
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends